Home Cart Sign in  
Chemical Structure| 1507370-20-8 Chemical Structure| 1507370-20-8

Structure of BC-1215
CAS No.: 1507370-20-8

Chemical Structure| 1507370-20-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BC-1215 exhibited maximal inhibitory binding at 10-7M, measured by quantification of bound Fbxl2 protein.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BC-1215

CAS No. :1507370-20-8
Formula : C26H26N4
M.W : 394.51
SMILES Code : C1(CNCCNCC2=CC=C(C3=NC=CC=C3)C=C2)=CC=C(C4=NC=CC=C4)C=C1
MDL No. :MFCD28118991
InChI Key :IXEPQJQQSLMESJ-UHFFFAOYSA-N
Pubchem ID :72201045

Safety of BC-1215

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HT22 cells 10 μg/mL 2 hours To confirm the pro-inflammatory effect of FBXO3 in the OGD/R model PMC9658360
Murine lung epithelial cells (MLE) 0, 0.4, 2, 10, 50 μg/mL 16 hours BC-1215 decreased TRAF1-6 protein half-life from 8–12 h to 3–4 h, without altering TRAF steady-state mRNA levels. PMC3845358
Human peripheral blood mononuclear cells (PBMC) 0, 0.4, 2, 10, 50 μg/mL 16 hours BC-1215 remarkably suppressed the majority of the Th1 panel cytokines including G-CSF, GM-CSF, GROα, I-309, IL1-α, IL1-β, IL1rα, IL-6, IL-12, IL-23, MIP-1α, MIP-1β and TNFα. PMC3845358
A549 cells 10 μg/mL 24 hours hypoxia followed by 4 hours reoxygenation BC-1215 significantly inhibited the H/R-induced increase in phospho-NF-κB p65 and decrease in IκB-α protein expression, and reduced IL-8 production. PMC6544082

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Lung ischemia-reperfusion injury model Added to the perfusate 0.1, 0.25, 0.5 mg/kg Single administration, observed for 100 minutes BC-1215 significantly attenuated I/R-induced lung edema, inflammation, oxidative stress, and apoptosis, and inhibited the activation of NF-κB and MAPK signaling pathways. PMC6544082
Sprague-Dawley rats Neuropathic pain model (spinal nerve ligation) Intrathecal administration 10, 30, and 100 nM Single bolus injection BC-1215 ameliorated SNL-induced behavioral allodynia by antagonizing TRAF2/TNIK/GluR1 signaling PMC6605509
C57BL/6 mice Sepsis model Intraperitoneal injection 500 µg, 100 µg, 20 µg, 4 µg and 0.8 µg Single dose BC-1215 exhibited high potency in vivo (inhibitory dose [ID50] IL-1β = 1 mg/kg, ID50 IL-6 = 2.5 mg/kg, ID50 TNFα = 1.2 mg/kg). PMC3845358
Sprague-Dawley rats Spinal nerve ligation (SNL) model Intrathecal injection 100 nM Single bolus injection BC-1215 attenuated SNL-induced allodynia by inhibiting Fbxo3 activity. PMC6601949

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.53mL

0.51mL

0.25mL

12.67mL

2.53mL

1.27mL

25.35mL

5.07mL

2.53mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories